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Abstract
Tissue availability of polyunsaturated fatty acids (PUFAs) is of major relevance for
health, and it depends on both dietary intake and metabolic turnover. We found close
associations between variants in the human genes of 5- and 6-desaturase, FADS1
and FADS2, and serum phospholipid contents of PUFAs and long-chain PUFAs (LC-
PUFAs). Polymorphisms and reconstructed haplotypes of FADS1 and the upstream
region of FADS2 showed strong associations with levels of the n-6 LC-PUFA arachi-
donic acid (20:4n-6). Carriers of the less common polymorphisms and their respective
haplotypes also had a lower prevalence of allergic rhinitis and atopic eczema. Our data
demonstrate for the first time that the fatty acid composition of serum phospholipids
is genetically controlled by the FADS1 FADS2 gene cluster. The investigated single
nucleotide polymorphisms in this cluster explain 28% of the variance of serum phos-
pholipid arachidonic acid and up to 12% of its precursor acids. Based on this genetic
variation, individuals may require different amounts of dietary PUFAs or LC-PUFAs to
achieve comparable biological effects. We strongly recommend including analyses of
FADS1 and FADS2 polymorphism in future cohort and intervention studies address-
ing the biological effects of PUFAs and LC-PUFAs, which should enhance the sensitiv-
ity and precision of such studies.
Copyright © 2008 Nestec Ltd., Vevey/S. Karger AG, Basel
The metabolic availability of polyunsaturated fatty acid acids (PUFAs) has
a major impact on human health. PUFA status has been related, among other
outcomes, to early visual, cognitive and motor development [1, 2], mental
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health and psychiatric disorders [3], cardiovascular disease mortality [4],
immunological and inflammatory responses as well as related diseases such
as allergies [5, 6]. These and other biological effects of PUFAs appear to be
mediated to a large part by the availability of the long-chain PUFAs (LC-
PUFAs) with 20 carbon atoms and 3 double bonds, such as the n-6 LC-
PUFA arachidonic acid (20:4n-6), and the n-3 LC-PUFAs eicosapentaenoic
acid (20:5n-3) and docosahexaenoic acid (22:6n-3; fig. 1). Preformed LC-
PUFAs are also supplied with some foods (e.g. arachidonic acid with meats
and eggs; eicosapentaenoic acid and docosahexaenoic acid with marine
foods). Dietary LC-PUFA supply has a marked effect on blood and tissue con-
tents which has been documented in numerous studies [7]. LC-PUFAs can
also be derived in human metabolism from the precursor essential fatty acids,
linoleic acid (18:2n-6) and -linolenic acid (18:3n-3), by consecutive desatu-
ration and chain elongation (fig. 1).
The activity of PUFA desaturation and chain elongation appears to be very
limited in humans [8], but there are numerous indications for considerable
inter-individual variation in the capacity for endogenous formation of LC-













































Fig. 1. Pathways for the conversion of n-6 (left) and n-3 (right) essential fatty acids
into LC-PUFAs by enzymatic desaturation and chain elongation. Modified from
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rather close correlation of n-6 and n-3 LC-PUFA contents in mature human
milk [9] (fig. 2), even though the main dietary sources of the two LC-PUFA
families are very different. Thus, it appears that some women have a higher
ability to synthesize and secrete milk LC-PUFAs of both the n-6 and the n-3
series than others.
A similar conclusion was drawn by Innis et al. [10] who observed a positive
correlation of docosahexaenoic acid and n-6 docosapentaenoic acid in red
blood cell phosphoglycerides of preschool children, in contrast to the recipro-
cal relationship found in animals where high n-6 docosapentaenoic acid levels
are a marker of low docosahexaenoic acid availability. The authors concluded
that the positive relationship of n-6 and n-3 LC-PUFA levels observed in these
children may reflect different activity levels of desaturases between individu-
als affecting the conversion of both the n-6 and the n-3 fatty acids.
Recently we repeatedly studied the dietary intake and fatty acid composition
of plasma phospholipids in a group of healthy children at the ages of 24, 36 and
60 months. As one might expect, dietary fatty acid intake patterns changed
markedly over time from the age of 2 to 5 years, and there was no correlation or
‘tracking’ of dietary intakes of saturated, monounsaturated and polyunsaturated
fatty acid over time. In contrast, there was a significant correlation (‘tracking’)
over the 3 time points of plasma phospholipid levels of n-6 LC-PUFA (r  0.67)
and the arachidonic acid/linoleic acid ratio (r  0.64), and to a lesser degree also
of n-3 LC-PUFA (r  0.32) and of the docosahexaenoic acid/-linolenic acid
ratio (r  0.32) [11]. This tracking of plasma LC-PUFA levels in the absence of
tracking of dietary intake patterns leads us to conclude that there is inter-indi-





















n-6 LC-PUFAs (% wt/wt) 
r20.64, p0.05
Fig. 2. Correlation of n-3 and n-6 LC-PUFA contents in mature human milk, sug-
gesting inter-individual differences in the ability to form LC-PUFAs. Modified from




















   
   
   
   
   
   
   
   
   
   
   





















these children, which persists over time and could most likely be due to geneti-
cally determined differences in metabolic turnover. Considerable inter-individual
differences in endogenous PUFA conversion have also been demonstrated in
stable isotope studies [12, 13], but these data do not reveal to which extent such
differences in PUFA conversion may be due to moderating nutritional, metabolic
and endocrine factors [8], or due to genetic variation.
The enzymes 5- and 6-desaturase are considered rate-limiting for the
enzyme-mediated conversion steps of this pathway [8]. Both desaturases are
expressed in the majority of human tissues, with the highest levels in liver but
considerable activity also found in the brain, heart, and lung. The hypothesis
that they play a key role in inflammatory diseases is strengthened by func-
tional studies in mice, in which selective 5- and 6-desaturase inhibitors
induced marked anti-inflammatory effects [14].
In human tissue, the regulatory mechanisms of 5- and 6-desaturases have
scarcely been examined. The human desaturase cDNAs were first cloned in
1999 and identified in 2000 as fatty acid desaturase-1 (FADS1, encoding 5-
desaturase) and fatty acid desaturase-2 (FADS2, encoding 6-desaturase) in
the human genome [15]. The two genes are located in a cluster on chromosome
11 (11q12–13.1) with a head-to-head orientation. The sequence of the FADS1
FADS2 gene cluster can be identified as a region of conserved synteny to the
mouse genes Fads1 and Fads2 coding for the homologous enzymes on mouse
chromosome 18, with the same head-to-head orientation and the same homolo-
gous adjacent genes (http://www.ensembl.org/Homo_sapiens/syntenyview).
Linkage was previously reported between or nearby the human chromosomal
region 11q12–13.1 and complex diseases like type-1 diabetes, osteoarthritis, and
bipolar disorders, as well as asthma, atopy and allergy-related quantitative traits
such as total and specific IgE levels [15].
Evaluation of the Effects of FADS1 and FADS2
Polymorphisms on LC-PUFA Status in Humans
In an attempt to explore the genetic determinants of PUFA metabolism, we
performed an analysis of 18 single nucleotide polymorphisms (SNPs) of the
FADS1 FADS2 gene cluster in 727 adult volunteers participating in the
European Community Respiratory Health Survey I (ECRHS I) [15]. In
1991–1992 a population-based sample of randomly selected, mainly Caucasian
subjects aged between 20 and 64 years, was recruited in the city of Erfurt,
Germany. Of the cohort of 1,282 participants who answered the main ques-
tionnaire, samples from 727 participants were available for genetic testing of
DNA, and deep frozen (80C) serum samples were used for analysis of
phospholipid fatty acid contents. The study protocol was approved by the
Ethics Committee of the Bavarian Board of Physicians at Munich. The analyzed
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positional and functional aspects to enhance the chance of detecting associa-
tions [15]. Genotyping of SNPs in the FADS1 FADS2 cluster was performed
using matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) to detect allele-specific primer extension prod-
ucts (Mass Array, Sequenom, San Diego, Calif., USA).
The results of genotyping confirmed that 18 SNPs reported in public data-
bases in the FADS1 FADS2 cluster were polymorphic, with a mean genotyping
success rate of 97.4%. The distributions of genotypes for all analyzed SNPs
were consistent with Hardy-Weinberg equilibrium. Redundant markers
(rs174545, rs174546, and rs174568) were left out of the analyses. Association
analysis of SNPs with fatty acids showed highly significant results for the
majority of the SNPs in the FADS1 FADS2 cluster and the n-6 and n-3 fatty
acids (p values 1.0*1013) except for n-6 docosapentaenoic acid (22:5n-6)
and docosahexaenoic acid (22:6n-3). Subjects carrying the minor alleles of the
SNPs rs174544, rs174553, rs174556, rs174561, rs174568, rs968567, rs99780,
rs174570, rs2072114, rs174583, and rs174589 exhibited enhanced levels of the
precursor fatty acids linoleic acid (18:2n-6), eicosadienoic acid (20:2n-6),
dihomo-	-linolenic acid (20:3n-6), and -linolenic acid (18:3n-3), and decreased
levels of the product fatty acids 	-linolenic acid (18:3n-6), arachidonic acid
(20:4n-6; fig. 3), adrenic acid (22:4n-6), eicosapentaenoic acid (20:5n-3), and
n-3 docosapentaenoic acid (22:5n-3) [15].
Haplotypes were statistically reconstructed for two different windows
(table 1). To avoid large reconstruction errors resulting from missing data,
the reconstruction was based only on persons from whom all genotypes were
available. The strongest associations were found in the first part of the gene
cluster. The second window was restricted to the first five strongly correlated
SNPs with r2 
 0.7, for which complete genotype data of 637 subjects was
available. For the 5-locus haplotypes, only two haplotypes had a frequency

5%, with the most common haplotype carrying the major alleles at all loci
(frequency 68%), and with the next frequent haplotype carrying only minor
alleles (frequency 26%). Haplotype association analysis indicated highly
significant associations also after correction for multiple testing (p values
multiplied by 17 for the 17 tested outcomes) between the haplotypes and the
fatty acid levels (examples for linoleic and arachidonic acid are shown in table 2).
Virtually all haplotypes carrying minor alleles were associated (p 1.0*1013)
with increased levels of linoleic acid (18:2n-6), eicosadienoic acid (20:2n-6),
dihomo-	-linolenic acid (20:3n-6), and -linolenic acid (18:3n-3), and with
decreased levels of 	-linolenic acid (18:3n-6), arachidonic acid (20:4n-6),
adrenic acid (22:4n-6), eicosapentaenoic acid (20:5n-3), and n-3 docosapen-
taenoic acid (22:5n-3), which was in line with the findings of the SNP analy-
sis. For n-6 docosapentaenoic acid (22:5n-6, after correction for multiple
testing) and docosahexaenoic acid (22:6n-3, uncorrected and corrected),
haplotype analysis – as the previous SNP association analysis – showed no




















   
   
   
   
   
   
   
   
   
   
   























their plasma concentration is moderated by the indirect synthesis via peroxi-
somal -oxidation.
Genotypes or haplotypes were not associated with total or specific IgE levels,
but carriers of the minor alleles of several SNPs had significantly reduced odds
ratios (ORs) for allergic rhinitis and atopic eczema: allergic rhinitis, rs174544
(OR  0.59, 95% CI 0.36, 0.99), and rs2072114 (OR  0.45, 95% CI 0.23, 0.88),
and atopic eczema, rs174556 (OR  0.49, 95% CI 0.25, 0.94). The 5-locus hap-
lotype consisting only of minor alleles showed protective ORs with allergic rhini-
tis (OR  0.46, 95% CI 0.26, 0.83) as well as with atopic eczema (OR  0.46,
95% CI 0.22, 0.94). The 11-locus haplotypes also showed a tendency towards
protective ORs. Thus, in this population-based sample we found that minor alle-





























































































Fig. 3. Association analysis of 15 SNPs with changes in the serum phospholipid
contents of the major n-6 LC-PUFA arachidonic acid (20:4n-6) versus mean values for
subjects carrying the respective major SNP on both alleles [major A major A].
  Changes in fatty acid composition for heterozygous carriers of the minor SNP
(level [major A, minor a] minus level [major A, major A]);   homozygotes of the
minor allele (level [minor a, minor a] minus level [major A, major A]). Heterozygotes
for the minor allele of the SNP rs174544 have a lower level of arachidonic acid (9.2%)
in comparison to homozygotes for the major allele (10.2%), whereas those
homozygous for that minor allele exhibit only 8% arachidonic acid (means  SE).
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two genes encoding the two relevant desaturases on the metabolic pathway
leading to arachidonic acid (20:4n-6) production, as well as their corresponding
haplotypes were highly associated with an increase in levels of linoleic acid
(18:2n-6), eicosadienoic acid (20:2n-6), dihomo-	-linolenic acid (20:3n-6), and
-linolenic acid (18:3n-3), and with a decrease in the levels of 	-linolenic acid
(18:3n-6), arachidonic acid (20:4n-6), adrenic acid (22:4n-6), eicosapentaenoic
acid (20:5n-3), and n-3 docosapentaenoic acid (22:5n-3), and less pronounced
in n-6 docosapentaenoic acid (22:5n-6) in human serum phospholipids. The
most significant associations and the highest proportion of genetically
explained variability (28%) were found for arachidonic acid (20:4n-6; table 3).
Implications of the Observed Genetic Effects 
on PUFA and LC-PUFA Status in Humans
Our findings highlight the contribution of the desaturation pathways on n-6
and n-3 PUFA and LC-PUFA levels in serum phospholipids, and the major
importance of its genetic control. Not only arachidonic acid (20:4n-6), but also
Table 1. Haplotype characteristics for 11-locus and 5-locus haplotypes
Haplotype Allelesa Frequency, %
11-locus haplotype (rs174544–rs174589)
MaAb CACTTGCCACG 11111111111 68.8
Haplo.1 AGTCdelATCATC 22222221122 10.6
Haplo.2 AGTCdelGTTGTG 22222122221 7.8
Haplo.3 CGCTdelGTTATC 12112122122 2.9
Haplo.4 AGTCdelGTCGTG 22222121221 2.6
Haplo.5 AGTCdelATCGTG 22222221221 1.2




MaA CACTT 11111 68.6
MiAc AGTCdel 22222 25.7
Haplo.1 CGCTdel 12112 3.5
Haplo.rare 2.3
(frequency 1%)
Adapted from Schaeffer et al. [15].
a1  Major allele; 2  minor allele.
bMaA  Major allele, haplotype carrying only common alleles.




















   
   
   
   
   
   
   
   
   
   
   























Table 3. Percentage of variations in the fatty acid levels explained by the SNPs for
the models containing the SNPs of the 5-locus and 11-locus haplotypes
Fatty acid R2 5 SNPs % R2 11 SNPs %
Linoleic acid (C18:2n-6) 8.6 9.2
	-Linolenic acid (ln C18:3n-6) 7.9 7.9
Eicosadienoic acid (C20:2n-6) 10.1 12.3
Dihomo-	-linolenic acid (C20:3n-6) 7.4 10.8
Arachidonic acid (C20:4n-6) 27.7 28.5
Adrenic acid (C22:4n-6) 6.3 5.9
n-6 Docosapentaenoic acid (ln C22:5n-6) 1.2 1.5
-Linolenic acid (C18:3n-3) 3.9 5.4
Eicosapentaenoic acid (ln C20:5n-3) 5.2 6.9
n-3 Docosapentaenoic acid (C22:5n-3) 5.5 5.1
Docosahexaenoic acid (C22:6n-3) 1.4 2.9
Table 2. Examples of associations of FADS1 FADS2 haplotypes with the major
dietary essential fatty acid, linoleic acid (18:2n-6), and the major n-6 LC-PUFA,
arachidonic acid (20:4n-6)
Haplotype C18:2n-6 C20:4n-6
Haplo.1 p 8.5*10–6 3.7*10–15
Coefficient 1.18 –1.03
Haplo.2 p 0.0066 1.0*10–14
Coefficient 0.95 –1.48
Haplo.3 p 0.0060 3.2*10–7
Coefficient 1.518 –1.266
Haplo.4 p 0.086 9.4*10–5
Coefficient 1.311 –1.124
Haplo.5 p 1.0 0.045
Coefficient 0.29 –1.066
Haplo.6 p 0.16 0.22
Coefficient 1.907 –0.955
Haplo.rare p 0.079 0.068
Coefficient 1.067 –0.564
MiA-Haplotype p 1.2*1013 1.0*10–14
Coefficient 1.18 –1.17
Haplo.1 p 0.024 1.3*10–7
Coefficient 1.177 –1.122
Haplo.rare p 0.32 0.70
Coefficient 1.067 –0.482
p values and -coefficients (change of fatty acid or change of log of fatty acid per
copy of the haplotype) are given. p values that exceed 1.0 after correction for multiple




















   
   
   
   
   
   
   
   
   
   
   





















its precursors, linoleic acid (18:2n-6), 	-linolenic acid (18:3n-6) and dihomo-
	-linolenic acid (20:3n-6), showed strong associations with the genetic vari-
ants. In free-living individuals with self-selected diets, the reconstructed
haplotypes explain a major proportion of the variation in plasma phospholipid
content, particularly of arachidonic acid where about 28% of variation of blood
levels is due to genetic variation (table 3), whereas the value is in the order of
10% for the precursor fatty acids of arachidonic acid. Smaller percentage val-
ues are found for n-3 fatty acids, which may reflect a higher importance and a
larger degree of variation in dietary intakes of both the precursor -linolenic
acid primarily from vegetable oils and the products eicosapentaenoic acid and
docosahexaenoic acid primarily from marine foods.
Conclusion
(1) Blood lipid levels of both PUFAs with 18 carbon atoms that are
conventionally referred to as the essential fatty acids, and of their biologically
active LC-PUFA derivatives, are influenced not only by diet, but to a large
degree also by genetic variants commonly found in a European population.
(2) Levels of docosahexaenoic acid are not significantly affected by the
SNPs studied, but dietary supply is the primary determinant of docosa-
hexaenoic acid values.
(3) The studied SNPs for fatty acid desaturation enzymes are associated
with allergic rhinitis and atopic dermatitis which supports the conclusion that
the availability of PUFAs affects allergic endpoints.
(4) At the same level of dietary intake of precursor PUFAs or LC-PUFAs,
the respective biological and health effects may markedly differ due to
genetic differences in their metabolism.
(5) Based on genetic variation, subgroups of the population may have dif-
ferent requirements of dietary PUFA or LC-PUFA intakes, respectively, to
achieve comparable biological effects.
(6) These relationships should be explored in more detail in different pop-
ulations.
(7) We strongly recommend including analyses of FADS1 and FADS2 poly-
morphism in future cohort and intervention studies addressing the biological
effects of PUFAs and LC-PUFAs, which should also lead to enhanced sensitiv-
ity and precision of such studies.
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Discussion
Dr. Isolauri: Thank you very much for these new aspects and challenges to the
food industry. Concerning the data on the effect of n-6 fatty acids and margarine in
allergy: are all margarines the same in n-6 composition and how well does spread on
bread reflect the whole fatty acid intake?
Dr. Koletzko: Margarine is only one of many factors affecting n-6 intake.
Margarines differ quite a bit in their composition. There are more and more mar-






















   
   
   
   
   
   
   
   
   
   
   





















is quite a variation but these were epidemiological studies which just looked at associ-
ations between dietary patterns and outcomes, and there are a number of studies with
large sample sizes that found an association which might or might not be due to
linoleic acid intake. We actually looked at this in an adult population, in a school-age
population, and in birth cohorts. In the adult population we found that both the
dietary intake of arachidonic acid and the plasma levels of arachidonic acid are to
some extent associated with allergic end points, allergic sensitization and allergic dis-
ease. The data are not very clear cut and there are somewhat different results in males
and females which might be explained by different dietary patterns and different
reporting patterns between males and females, but there is some association. If
there is such a strong effect of genetic variation, dietary data alone will not give the
full picture.
Dr. Prescott: Thank you very much for your very important work which clearly
illustrates that we need to look at this in our studies. In our work in Perth we have
recently shown that fatty acid supplementation in pregnancy can modify T-cell signal-
ing pathways, particularly protein kinase C isozymes which we also showed had a pro-
tective effect on allergic disease. Clearly we need to talk about looking at potential
polymorphisms and how that might modulate these effects. We also have another
larger cohort of 400 children in which we are looking at the effect of fish oil supple-
mentation on early immune function and allergy prevention. My question is how do
you think that high dose fish oil in pregnancy may have epigenetic effects on the baby?
Dr. Koletzko: Those are obviously issues that one might want to study and you
clearly have populations to look at that. If I recall correctly your first study was in 100
mothers who had a very high dose of long-chain n-3, which is a huge dose relative to
the potential impact on endogenous metabolism. We have done a similar study with
300 women using a lower dose of 500 mg DHA and the results are very similar to yours in
terms of modification of immune phenotypes in the newborn infants. I am very excited
about the potential of using omega-3 fatty acids as a preventive intervention in preg-
nancy. Perhaps we should join our cohorts together to search for polymorphisms. We
have material left that could be used for epigenetic analysis and I think this would be
an exciting opportunity.
Dr. Waterland: You spoke of these different haplotypes consisting of clusters of
SNPs, but where were the SNPs located? Were they within the coding regions or
within the regulatory regions of the genes? The contra-oriented juxtaposition position
of FADS1 and FADS2 suggests the potential for a shared regulatory region. I wonder if
you have explored the potential epigenetic regulation of those two genes?
Dr. Koletzko: We certainly did not look at epigenetic aspects in this study. We just
had DNA available from these subjects and we looked at the polymorphisms. The
SNPs were primarily exon SNPs with functional relevance although exon SNPs with-
out known functional relevance were not fully excluded.
Dr. Hofstratt: Is there a kind of market for having a genetic test go with a mar-
garine or other food stuffs?
Dr. Koletzko: That is the whole question behind personalized nutrition, where we
come to a situation in which people choose their food products and make dietary
choices according to differences in biological predisposition and genetic variation. At
least in Europe I am not sure that in the near future people will go into a supermarket
and take a quick blood test and then look for the products that are labeled green, blue
and red. I am not sure this is within reach for the general consumer market, but it is
certainly in reach for clinical nutrition. For example fish oil interventions are now used
in intensive care with the concept that an inflammatory response can be reduced and
outcome improved. In a clinical setting I can see that happening with the rapidly advanc-
ing methodology. With pharmacological agents we test for genetic polymorphisms





















   
   
   
   
   
   
   
   
   
   
   





















before we give a drug we could do the same with the fatty acid polymorphisms to dose
the fish oil intervention. Will this be happening with respect to the general consumer
market? What would consumer research at Nestlé say? Is this something that we can
expect in the next 15 or 20 years?
Dr. Rinaldo: I work in a biochemical genetics laboratory and in recent years we
have faced a dramatic increase in requests to measure polyunsaturated fatty acids
(PUFAs) for all sorts of studies beyond my primary area of interest which is inherited
disorders of fatty acid oxidation. We are testing patients who are under lipid-restricted
diets. A major issue that came up in these studies was that historically plasma PUFA
results have been expressed as a percent of the total amount. Once I showed our col-
laborators and colleagues results expressed using absolute amounts, and some of the
variabilities in plasma you mentioned earlier disappeared. In your presentation, your
results were expressed as a percent of a total, so I would like to know if the reported
differences between genders and other variabilities could be a confounding factor in
the evaluation of this polymorphism?
Dr. Koletzko: A number of people have looked at that comparing absolute concen-
trations, milligrams per liter for example, to percentage of fatty acids in e.g. phospho-
lipids or total lipids. It is a complex question but my understanding of the literature
and also my experience with our own measurements is that the percentage data show
much less variation than the absolute data. If there is a change in the total concentra-
tion of lipid fractions, if the lipoproteins go up and down, the relative proportion of
fatty acids does not necessarily change. Moreover, there are a number of studies
which have associated end points with plasma levels, and it was clearly shown that the
correlation to phospholipid percentage data was much closer than to the absolute
data, and also much closer than to the red blood cell levels, which are often considered
the best determinant of fatty acid status but I have considerable doubts. With respect
to the inborn errors I agree with you that there are a number of unresolved questions.
We also looked at samples from -oxidation disorder patients and we have often found
extremely low DHA values and patterns with classical essential fatty acid deficiency
with an increased Mead acid, which is clearly a problem that needs to be looked at in
further detail. We have indications from a population of children with phenylketonuria
(PKU) that the supply matters. Both our group [1] and the group in Milan [2] have
shown that DHA supplementation to children with PKU improves electrophysiology,
latency time, and speed of information processing. In the Journal of Pediatrics we
also published that supplementation with DHA in PKU children improves fine motor
coordination and some other simpler behavioral responses [3]. Yes, there is really
room to look at this in further detail in children on restricted diets.
Dr. Rinaldo: That is exactly the point; in some patients with long-chain fatty acid
oxidation disorders the percent estimate indicated a DHA deficiency when the values
were looked at as absolute amounts, where actually comfortably within what we had
defined as the age-matched reference range, which was really the type of discrepancy
I was referring to. What would be your advise; should we overrule a normal absolute
amount because as a percent it appears to be low?
Dr. Koletzko: I am not claiming that I have the final answer and we probably need
to look at this in further detail, particularly under extreme conditions such as a
severely restricted diet which might be very different from other situations. However,
the data that are available indicate that percentage values are more predictive of
functional response, and in a way it is plausible because if you think of circulating
plasma lipids they would be exchanged presumably as a lipid with tissue and not
selectively as one fatty acid. This is somewhat speculative and I really suggest we need
to look at this further. In the animal world, however, there are also data relating tissue






















   
   
   
   
   
   
   
   
   
   
   





















Dr. Haschke: I would like to comment on what consumer researchers at Nestlé
should do in the future. This is not a subject for consumer research. The matter is
much too complex and complicated. If you look at the pharma industry where poly-
morphisms are clearly associated with different drug metabolisms, the message is not
even understood by most medical doctors. There are a few who are focused and apply
the methods. As we have learned from the pharma industry, the future for the nutri-
tion industry will be to develop research organizations like the pharma diagnostic sec-
tions, which are the most rapidly developing sections in the pharma industry. If you
look at Roche or Bayer, for example, their diagnostic sections are just booming. The
message must be focused, and the outcome must be affordable because if nobody can
pay for the findings, it will be very difficult to transfer them to a consumer message.
The prices for chips have come down, one thousand-fold within half a year now. If
there is a future for this kind of research, then the nutrition companies are well
advised to establish diagnostic sections and also focus on the product outcome just as
the pharma industry is doing.
Dr. Koletzko: As you alluded to, the price barrier will no longer be a barrier for
diagnostic testing in the foreseeable future, and it will depend on consumers who
understand that there is a clear advantage to applying this. If, for example, the results
from this first study on the predictive effects on allergic end points are confirmed,
then I am sure many families will want to know this and will probably adapt the dietary
pattern for their children if there is evidence that this is of benefit for them. In a way
we are not far away from that. It is very clear that for a child with inborn errors the
dietary pattern can be adapted by focusing on the phenotype or genotype. Many peo-
ple will also do this if they have a high cholesterol value; they will take dietary advice
based on their high cholesterol value and will buy a margarine with phytostanols based
on that finding. So I don’t see that this is very far away. If people find the information
that this is of benefit for them, then I am sure it will happen.
Dr. Gluckman: In our rodent studies we find that FADS1 and FADS2 are two of
the most sensitive genes, a life-long expression from fetal undernutrition. So there are
probably genes that are already subject to quite a lot of direct or indirect epigenetic
regulation. They tend to move together.
Dr. Koletzko: That is exciting information that I would like to hear more about.
The question then also rises can we study that in humans and can we find similar pat-
terns?
Dr. Gluckman: The dilemma is what tissue, because this is a matter of the meta-
bolic reactive tissues. I would doubt that you see it just by studying blood. I think that
is the dilemma of epigenetics; that it is so often tissue-specific effects as opposed to
global effects.
Dr. Koletzko: We assume that most of the desaturation in humans occurs in the
liver, and liver biopsies are actually done in humans. If you don’t need much material
perhaps there are opportunities.
Dr. Laitinen: You started your talk by showing the scheme on n-3 and n-6 fatty
acids and their immunological effects, and you also presented the thought that n-3
fatty acids are the good ones: they have a lot of beneficial effects in immunological
terms, and this has indeed led to supplementation studies with interesting results as
well. But there are also some studies showing that there might be some risks, for
example one study looking at n-3 fatty acids in breast milk showed an increased risk of
atopy. So what are your thoughts on this increased trend of supplementing with n-3
fatty acids and could these new results of yours on genetic variation contribute to
this?
Dr. Koletzko: Obviously we have very little information so far on the effects of the
supplementation in the perinatal period in pregnancy and in the lactation period on





















   
   
   
   
   
   
   
   
   
   
   





















allergic end points. The studies that Dr. Prescott and our group have done do not give
sufficient evidence yet to really draw firm conclusions, and we need to look at this fur-
ther. However, the early nutrition programming project together with the perinatal
lipid nutrition project and seven international scientific societies have just brought out
a position paper recommending that pregnant and breastfeeding women should aim at
achieving a dietary DHA intake averaging at least 200 mg/day based on reduction of
early preterm birth, and also based on the reported benefits on outcomes in child
development [4]. This is already a very strong data set which this group of 50 interna-
tional scientists looked at in an evidence-based way, supporting that some supply of
long-chain n-3 during pregnancy is beneficial, not necessarily for allergy though, and
there we need more good studies.
Dr. Isolauri: At the enterocyte level the effect of n-6 fatty acids appears to be sup-
pression of T-cell proliferation and an increase in IL-10 production, and that of n-3 is
also associated with dendritic cells producing IgA. Therefore we do not have enough
data to support one over the other.
Dr. Koletzko: Everybody in science knows that the world is usually not as simple
that there is just good and evil. In the real world, particularly in biology, things are usu-
ally more complex and to say arachidonic acid is bad and eicosapentanoic acid is good
is probably an over-simplification. It doesn’t reflect what is really happening in biology.
Dr. German: Actually now this population has been identified, wouldn’t it be a
very valuable resource to discover what else is affected by arachidonic acid and there-
fore likely be beneficially sensitive to things like n-3? You talked about allergic rhinitis;
what else do they get?
Dr. Koletzko: This is a cohort that was recruited in 1991 and 1992, and it was
recruited with this specific perspective to look at respiratory health and respiratory
allergy. So the phenotyping in that area is very good and that is why we took that pop-
ulation because it was convenient: the blood was there, DNA was there, the phenotyp-
ing was there, but we don’t have a very good description of other outcomes in this
population. However, there are other cohorts, we are now working on a cohort of chil-
dren trying to look at the same question and with different phenotype descriptions.
Again I would like to reiterate if any of you is embarking on either cohort or interven-
tion studies grab the opportunity and look at those polymorphisms. If you can’t do
them yourself we will be happy to collaborate and do it because it is a very simple, high
throughput measurement. It would be worthwhile to look at in many different popula-
tions and see what the effects might be.
Dr. Gluckman: Are there any gender-specific effects in these studies? I mention
this because quite gender-specific effects of other polymorphisms, such as PPAR
polymorphisms, and the relationship between PUFA intake and, e.g., plasma choles-
terol or other lipoprotein-related levels in blood have been seen.
Dr. Koletzko: We can’t really draw conclusive evidence from the our population.
But in the epidemiological studies by Trak-Fellermeier et al. [5] for example, there are
differences in the relationship between dietary fatty acid intake and allergic response
between men and women. It is very difficult from an epidemiological study to decide
why that is. Obviously women have a different food intake pattern, less energy and
less fat intake, and they also tend to be more conscious about the food selection in
general. They may be better in reporting dietary patterns than many men. So it is very
difficult to understand to which extent this is a biological difference, and to which
extent it is a behavioral or other difference.
Dr. German: Does this polymorphism predict sensitivity to n-3 supplementation
for anti-inflammatory effects?
Dr. Koletzko: It needs to be studied and perhaps with Dr. Prescott’s data one could






















   
   
   
   
   
   
   
   
   
   
   





















Dr. Nassar: Based on the anticipated benefits and despite the hazards, do you
recommend supplementation of n-3 to patients with protein energy malnutrition?
Dr. Koletzko: Obviously n-3 fatty acids are essential substrates which one wants to
include in a dietary supply. We tend to think that, at least in children, DHA is an essen-
tial substrate based on the observation that in children with PKU and a restricted
intake of DHA, functional disturbances can be overcome with DHA supplementation.
Probably children generally should have some supply of DHA. However, in a situation
of nutritional rehabilitation after malnutrition, I would suggest that this should be
closely studied. There are potential benefits similar to the situation in the critically ill.
But once it has been studied, I think one would feel much more comfortable because
one could not totally exclude that there might also be adverse effects. Obviously in a
state of protein energy malnutrition there is often a reduction in anti-oxidative
protection and it is conceivable that there might be more oxidative stress if omega
3 fatty acids are supplied, particularly in a combination with ascorbic acid, iron or
other prooxidants. The other question regards a situation with a high risk of infection;
if a high dose of an immunosuppressant substrate is given, there is a potential that
infectious risk increases. I am not sure this would happen, I am not saying one should
not do it, I am just saying in my view it would be worthwhile to study in a controlled
fashion: supplement one group and another group not, and see what the effects are on
such end points.
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